Monday, 25 August 2008

VitiGam� Inhibits Melanoma Growth In A Dose Dependent Manner - Inhibition Of Tumor Growth Is Statistically Significant

�GammaCan International, Inc. (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, announced further progress in its VitiGam� development program. In cookery for its upcoming IND submission for VitiGam�, the Company successfully completed extra experiments victimisation its established mouse melanoma model. These studies demonstrate a dose response of tumors (human melanoma cells) when treated with IgG preparations derived from vitiligo donors. In addition, the Company has conducted a meta-analysis (a statistical analysis of a large number of experiments) based on a series of antecedently announced studies with its mouse melanoma model. The results of this meta-analysis further confirm the effectuality against melanomas of IgG preparations derived from vitiligo donors.


Using the A375 human malignant melanoma cell communication channel in SCID mice, the Company demonstrated that vitiligo-derived IgG preparations can prevent the growth of melanomas in a dose dependent manner. In these studies, mice with subcutaneously induced melanomas were treated with varying concentrations of vitiligo-derived IgG preparations and compared to saline treated mice. At higher doses, vitiligo-derived IgG preparations reduced neoplasm sizes by fifty percent and greater when compared to turn down doses.


The Company likewise conducted a meta-analysis to further confirm the overall effectiveness of vitiligo-derived IgG preparations against melanoma cells. This analysis revealed a specific and highly statistically significant inhibition of neoplasm growth in mice treated with vitiligo-derived IgG preparations. Specifically, the Company ascertained that deuce separate pools of vitiligo-derived IgG preparations were able to inhibit tumor growth in a highly statistically significant mode (p=0.006) compared to control mice receiving saline. In gain, this analysis substantiated that anti-melanoma effects are specific to vitiligo-derived IgG preparations. Tumors in mice treated with vitiligo-derived preparations were significantly smaller (p=0.043) when compared to tumors in mice treated with IgG preparations from non-vitiligo donors.


Steven Katz, Chairman of the Board and President of GammaCan aforementioned, "These analyses confirm the validity of our anti-melanoma program. Using our models, we have repeatedly demonstrated that vitiligo-derived IgG preparations can foreclose tumor growth. Further, we have observed a dose response to vitiligo-derived IgG-based therapy." Mr. Katz further commented that, "These positive results keep to retain us on track to file our IND with the U.S. Food and Drug Administration in the near condition."

About GammaCan


GammaCan develops proprietary immunotherapy and related to approaches to treat malignant melanoma and other cancers. GammaCan's patented platform technology is based on the employment of IgGs (gamma-immunoglobulins), a safe, comparatively non-toxic human plasma-derived product used to treat a variety of immune deficiencies and autoimmune diseases. In cancer, IgG-based therapies work by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to chemotherapy. The Company's star drug nominee, VitiGam�, targets Stage III and Stage IV melanoma for which no effective treatment currently exists. In August 2007, VitiGam� standard Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the intervention of Stage IIB to Stage IV metastatic malignant melanoma. For more than information around GammaCan, visit http://www.GammaCan.com.


About VitiGam�


VitiGam� is a first-in-class IgG-based anti-cancer immunotherapy being highly-developed for the treatment of Stage III and Stage IV malignant melanoma. GammaCan is planning to submit its Investigational New Drug Application (IND) for VitiGam� to the FDA in the near next. The Company expects to commence human clinical trials shortly thereafter. VitiGam� is an IgG-based product manufactured from the plasma of donors with Vitiligo, a benign skin condition poignant up to 2% of the general population. Studies have shown that this "enriched" IgG formulation contains potent anti-melanoma activity. Based on these studies, GammaCan expects VitiGam� to put up specific anti-melanoma activity against melanoma cells, as well as nonspecific anti-cancer activity.

About Melanoma


Melanoma is a deadly form of skin cancer. According to the American Cancer Society, melanoma accounts for some 4% of all skin cancers just causes about 75% of all skin cancer-related deaths. An estimated 62,500 people testament be diagnosed with metastatic melanoma (Stage III and Stage IV) in 2008; the prognosis is poor since no effective treatment currently exists. These patients have a median endurance time of 8.5 months and a 5-year survival pace of less than 10%. There has been minuscule change in these results for in excess of 25 age. The incidence of melanoma has increased more speedily than whatsoever other crab during the past 10 years. The last dose to treat patients with metastatic malignant melanoma was approved by the FDA over 30 days ago.


Safe Harbor Statement


Statements in this squeeze release that are non purely historic are modern statements. Forward-looking statements in this press out release include statements regarding: the commercialisation of antineoplastic immunotherapies and the Company's efforts to develop therapies to promote the immune systems of cancer patients by the use of IgG-based therapy. Actual outcomes and the Company's literal results could differ materially from those in such forward-looking statements. Factors that could causal agency actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology; the inability to hire set aside staff to develop the technology; unlooked-for technical difficulties in development the applied science; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise preferred for consumers; the unfitness to market a product; all of which could, among other things, detain or prevent product release, as well as other factors explicit from time to time in GammaCan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press outlet should be read in conjunction with GammaCan's periodic filings with the SEC, which are incorporated herein by acknowledgment. The advanced statements contained herein are made entirely as of the date of this press release and GammaCan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

http://www.GammaCan.com


More information

Friday, 15 August 2008

Jerry Lewis says gun in baggage was telethon gift

LOS ANGELES () - Comedian Jerry Lewis aforesaid the pistol seized from his baggage by drome security in Las Vegas last month was an engraved gift given to him during his yearbook telethon for the Muscular Dystrophy Association.





The 82-year-old entertainer, world Health Organization was detained by law after the incident at Las Vegas McCarran International Airport, explained why he was carrying a firearm in an interview with the TV show "Entertainment Tonight" airing on Thursday.





"I had a

Thursday, 7 August 2008

James Garner - Garners Daughter Dads Fine

The girl of honey actor JAMES GARNER has assured fans her fatherhood is "doing fine" after recent photographs of the frail headliner sparked concerns for his health .

Garner was snapped visiting a Beverly Hills, California hospital, looking for gaunt and distant, simply his source daughter Gigi insists the pictures ar deceiving.

She says, "He had a stroke on May 9th but he's doing well. He's doing really well in fact. He's perfect."

The 80-year-old star, world Health Organization spent three weeks in hospital afterward undergoing surgery following his stroke, was photographed clutching a cane as a nurse and his number one wood helped him into a wheelchair.

His illustration says, "Jim was at the aesculapian centre for a routine outpatient check up with his mD."





More info

Friday, 27 June 2008

Ovuca

Ovuca   
Artist: Ovuca

   Genre(s): 
Electronic
   Rock
   



Discography:


Wasted Sunday   
 Wasted Sunday

   Year: 2001   
Tracks: 22


Onclements CD1   
 Onclements CD1

   Year: 2000   
Tracks: 41




 





Gustav Leonhardt - harpsichord.

Sunday, 22 June 2008

Sorma

Sorma   
Artist: Sorma

   Genre(s): 
New Age
   



Discography:


Mirage Of The East   
 Mirage Of The East

   Year: 1999   
Tracks: 10


Illusion   
 Illusion

   Year: 1999   
Tracks: 9




 






Saturday, 14 June 2008

Lil Wayne Announces Pact With Musicane to Sell Downloads of His Upcoming Tha Carter III Release Direct to Fans

Lil Wayne (http://www.Rapweekly.com/http://www.Rapweekly.com/www.lilwayne-online.com) will sell downloads of his highly anticipated Universal Motown release, Tha Carter III directly to fans via his website, social network pages and official blog using the Musicane widget -- a viral player with embedded commerce capability. Lil' Wayne's Musicane widget will be posted on all of his official sites offering fans a chance to buy the entire album and/or individual songs directly from his page. The player will also stream previews of the album, promotional interviews and, in the immediate future, merchandise and other products. The digital music downloads sold via Lil' Wayne's Musicane will be 320 kbps DRM-free MP3's, assuring that the music will be playable on a broad array of portable and home music players including Apple iPod's and iTunes.
"Lil Wayne is a natural fit to help further this movement not just because of his stature in the music world but more for his bold attitude toward change. He knows that the new model for the flow of music distribution is rooted in empowering the fans, not the traditional gate keepers that tend to slow everything down," says Musicane President and COO Vikramaditya Jain.
Musicane enables direct retail of digital and physical product through artist websites, as well as through embedded widgets that sit on users' personal websites, blogs and social networks. Billing, payment processing and delivery are also incorporated into the widget. Fans can post Lil Wayne Musicane widgets onto their own social media profiles, allowing them to share in the revenues generated through sales made from their widget. This 2-way relationship represents a fundamental shift in the traditional top-down approach that record labels have relied on in the past. Now fans and key "influencers" can virally participate in the launch of an artist's release and be rewarded for their efforts.
Lil Wayne will release Tha Carter III June 10th fresh off the success of the albums debut smash "Lollipop", which reached #1 on the Billboard Hot 100 chart. Tha Carter III, the last of his 'Carter Trilogy', has been called by XXL "The number one most anticipated album of the year." With production from Kanye West, Swizz Beatz and Alchemist among others as well as collaborations with Jay-Z, Busta Rhymes, Lil Mama, Ludacris, Fabolous, Juelz Santana and Robin Thicke The Carter III promises to be one of music's biggest releases.
Musicane, a media distribution and social shopping company founded by internet entrepreneurs Vikramaditya Jain and Sudhin Shahani. In September of 2006, Black Eyed Peas' frontman Will.i.am became a partner in the company.
Earlier this year, The Universal Music Group inked a deal granting Musicane a license to sell its entire catalogue in MP3 form via Musicane's network of websites, widgets and media players. To date, Musicane has generated over 50 million impressions and created incremental retail sales around album release campaigns of up to 55%. Recently, Musicane garnered attention for its distribution of Saul Williams' newest album The Rise and Fall of Niggy Tardust. Nine Inch Nails frontman Trent Reznor came out in support of the company's distribution services in an interview with New York Magazine.
See the Musicane widget on Lil Wayne's website http://www.Rapweekly.com/http://www.Rapweekly.com/www.lilwayne-online.com









Sunday, 1 June 2008

Marc and Cerys to spend Christmas together

Marc Bannerman and Cerys Matthews are reportedly planning to spend Christmas together.
The 'I'm A Celebrity.' couple, who have been spending time together at Matthews' home in England, are reportedly looking forward to getting to know each other better over the next few weeks.
Speaking to OK magazine Matthews said: "He's going to help me put Christmas decorations up. Life is really nerve-wracking all of a sudden because we're in the middle of all this. But I can't stop smiling. I'm still getting tummy flips."
Bannerman also revealed that he was thrilled at how well the relationship was going. He said: "It's a very unusual situation. I've never spent 24 hours a day with someone - normally there has been a break in between where you separate, but this has been so quick and intense.
"I definitely felt nervous on the drive here. I knew how I was feeling but I didn't know how she was feeling. I felt like a teenager again."
Earlier this week police visited the actor during his stay at Matthews' parents' house in Trefin in connection with an incident with a photographer last Friday.
The pair said they would stay at Matthews' home for the immediate future.